Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
This strategy is running out of steam.
Analysis of: How a Drug Maker Tries to Outwit Generics | online.wsj.com
Author: GLG Expert Contributor
These strategies are running out of steam as insurers, and even the general public, are catching on.  Most insurers will only pay for generic modafanil, and these new versions will not sell as much as they would have even 5 years ago.  The abuse potential of the drug may help, as brand-name...
Robert ArisNovember 18, 2008
Oral Treprostinil: An effective medicine hiding in a study with a challenging design?
Analysis of: Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint | ir.unither.com
Author: Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
October 2, 2008
COPD Drugs - Some safer than others
Analysis of: COPD Medicines: Risky or Safe? | www.webmd.com
Author: GLG Expert Contributor
In a recent article it is noted that for users of Ipatropium bromide there was an increase in all death and cardiac death in the group studied.  Theoretically at doses normally used there is not much of a corresponding mechanistic risk.  Therefore at this time additional study must be done...
August 21, 2008
Minimal Impact on Stent Market
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time | www.bloomberg.com
Author: GLG Expert Contributor
Because equivalent results were shown, there will be no change in stent placement volumes.
August 8, 2008
This makes a lot of cents...
Analysis of: Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com
Author: GLG Expert Contributor
I think that we primary care doctors have known all along that controlling several risk factors that we commonly see not only makes people live longer, but also more "intact" as they age.  I can look back over the last 28 years of practice and see that those patients who went downhill faster were...
August 4, 2008
Cure is a strong word
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
It is important to remember that there are many more "treatable" cancers diagnosed than curable cancers. The initiation of chemotherapy after surgical removal of a neoplasm is a signal that there may be undetectable metastatic disease.  You are therefore hoping for a cure but accepting the reality....
July 21, 2008
Healthcare industry NOT immune to economic illness
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor
The idea that people will always buy prescription and OTC drugs and will go to the physician and dentist, no matter what the economic conditions in the country, is, in my opinion, erroneous.  People's first priorities are getting to work (requiring gas), food, and shelter.  The most money...
Robert ArisJuly 18, 2008
Mild PAH improved by early treatment with bosentan
Analysis of: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. | www.sciencedirect.com
Author: Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients.  This is important because the definition of functional class II is that a patient has a sight...
July 3, 2008
Yes - please stop the cycle of 70 deaths then pull the drug!
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market.  Getting in front of this "problem" would improve the safety of our drug supply.
David EnglerJuly 2, 2008
They'll fix this before the end of the month
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: David Engler, Physician, The Allergy Clinic
If this isn't fixed, it won't be long before cognitive specialties, like internal medicine and neurology, start capping their practices and not allowing new Medicare patients.    

Page : 1 2 3 4 5 6 7 8 Next1 to 10 of 77

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203